Journal
CLINICAL RESPIRATORY JOURNAL
Volume 10, Issue 3, Pages 333-341Publisher
WILEY
DOI: 10.1111/crj.12222
Keywords
chest X-ray; low-dose computed tomography; lung cancer; meta-analysis
Categories
Funding
- Shanghai Committee of Science and Technology [13430720500]
- Shanghai Leading Academic Discipline Project [B115]
- National Natural Science Foundation of China [81472175]
- Shanghai Committee of Science and Technology [13430720500]
- Shanghai Leading Academic Discipline Project [B115]
- National Natural Science Foundation of China [81472175]
Ask authors/readers for more resources
Background and AimsLow-dose computed tomography (LDCT) has been proposed to be a new screening method to discover lung cancers in an early stage, especially those patients who are in a high risk of lung cancer. The primary objective of this meta-analysis is to systematically review the effect of LDCT on screening for lung cancers among the risky population who are older than 49 years old and with smoking exposure. MethodsWe searched randomized controlled clinical trials (RCTs) about comparing LDCT and chest X-ray or usual caring from MEDLINE, EMBASE, and the Cochrane Library, Web of Knowledge and Springerlink databases (January 1994 to September 2013). ResultsNine RCTs met criteria for inclusion. Screening for lung cancer using LDCT resulted in a significantly higher number of stage I lung cancers [odds ratio (OR) 2.15, 95% confidence interval (CI) 1.88-2.47], higher number of total lung cancers (OR 1.31, 95% CI 1.20-1.43) than the control. Four of the nine studies indicated that the screening method did not decrease all-cause mortality (OR 0.96, 95% CI 0.90-1.02), but decreased lung cancer-specific mortality (OR 0.84, 95% CI 0.74-0.96). Five studies showed that LDCT had higher false-positive rates (OR 8.7, 95% CI 7.43-10.19) than the group of control. ConclusionAmong the risky population, LDCT screening find out more stage I lung cancers and total lung cancers compared with chest X-ray or no screening, and also shows advantages in decreasing lung cancer-specific mortality, but the screening method does not decrease all-cause mortality and have a higher false-positive rates in diagnosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available